You could be eligible for a new phase II trial for CIDP

(chronic inflammatory demyelinating polyradiculoneuropathy)

RECRUITING NOW: RDMD is recruiting patients for CIDP research, including a new phase II clinical trial. You can read more about the trial at

To move this research forward, we need to pre-screen 200 patients. Patients cleared by RDMD are more likely to qualify for the trial. If you are not a good match, or aren’t interested in this trial, you can still participate in future RDMD CIDP research by joining below.

0/250 research participants
Complete the sign up in 10-15 minutes and we do the work to complete your pre-screen.
Mens Health Magazine
Mens Health Magazine

Who’s involved?

Reza Seyedsadjadi - (Consultant - Assistant in Neurology MGH)
Reza Seyedsadjadi - (Consultant - Assistant in Neurology MGH)
RDMD Research for CIDP is approved and monitored by an independent ethics review board called WIRB (Western Institutional Review Board). WIRB is a group of people who review research studies to protect the rights and welfare of human subjects. They provide in-depth regulatory expertise to support development of research protocols and documentation.Read more.

Why join the CIDP program?

Key benefits for you:

Reduce the time for chronic inflammatory demyelinating polyradiculoneuropathy drug development

All your medical data in one place

Follow new clinical trials

Make your de-identified health information part of multiple research projects

Your dashboard
Your dashboard

Our work with CIDP research

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-related neurological condition that causes damage to peripheral nerves. Most patients are diagnosed between the ages of 40 and 60. In CIDP, nerve damage causes progressive leg and arm weakness that makes it difficult to walk, go up stairs, and perform fine motor skills. Current treatments for CIDP do not work for everyone, so new treatments are still needed.

The latest on our research: RDMD is currently recruiting patients for a new phase II clinical trial for CIDP. Patients cleared by RDMD are then more likely to qualify for the trial. This is the first time RDMD has been involved in a phase II trial, and we are learning how we can make this process even simpler and easier for patients in the future.

  • Jumpstart
  • Accelerate
  • Insights

The CIDP program is in the jumpstart stage.

Be part of research

How it works

Sign up

1. Sign up

Create your private account and review our research consent (takes about 10 minutes)

We get to work

2. We get to work

We do all the behind-the-scenes work to retrieve and process your records

Empower research

3. Empower research

Track your contribution to research projects and, based on your records, find out if you qualify for new clinical trials based on your records

Be part of research

Questions? Check out our FAQ

Our values & principles.

Patients own their data

We believe that the only way to keep data accessible to the researchers who need it is by enabling patients to own and control their own data. Patients decide for themselves whether they want to privately and securely contribute to research, rather than having the decision made on their behalf.

We protect patient privacy

We abide by a strict research consent and privacy policy. We only share de-identified data with researchers, foundations, and therapeutic companies with patients’ consent. Protecting the privacy of patients and ensuring the security of their information is our highest priority.

Researchers gain access

We aim to make useful data accessible to all researchers who have legitimate research questions or research programs. For academic research, we offer access without charge. We take research ethics seriously, and we have policies in place to ensure that research is conducted with integrity.

Inclusiveness in the community

We don’t like to take sides—we give all members of the community the option to get involved. Success in rare disease research takes a village and we always welcome additional collaborators who can advance and benefit from the mission.

Driving forward therapeutic development

Our primary mission is to accelerate drug development, so we prioritize generating insights specifically relevant to therapeutic research. We invest deeply in quality, security, and compliance to make this a reality.